We help healthcare companies expand into new markets.
Need a distributor, CE Mark path, FDA strategy, hospital introductions, or a full market-entry plan? GHMAP delivers a reviewed package for your product and target country — then walks you through next actions.
From $500 strategy sessions to $2,500 Market Entry Sprints. See pricing · Meet the founder · Response within 24 business hours. Professional review required before business use.
Registration Progress
Reimbursement
Dossier in preparation
G-BA benefit assessment pathway
Distributors
Hospitals
Timeline
Required Documents
AI Summary
High confidenceGermany registration is on track for the classification and submission stages. Reimbursement filing depends on the completed clinical evaluation report. Professional review is required before relying on this summary for decisions.
Next action
Complete clinical evaluation report
Evidence-based answers, not a chat window.
Every answer is structured around sources, confidence, and what still needs professional review — never a bare conclusion.
Can EZDebride enter Kenya?
Answer
Kenya Pharmacy and Poisons Board (PPB) medical device registration pathway. Class II wound-care classification likely applies, pending final classification review.
Recommendation
Proceed with PPB Class II registration. Resolve local labeling requirements and import tariff classification before submission.
Required certificates
- CE Mark or FDA 510(k) equivalence file
- ISO 13485 quality management certificate
- Certificate of Free Sale
- KEBS conformity assessment
Hospitals
- Nairobi Central Medical Center
- Rift Valley Regional Hospital
- Coast Provincial Hospital
Distributors
- East Africa Health Partners
- Great Lakes Medical Distribution
Evidence & sources
Missing documents
- Local labeling requirements not yet verified
- Import tariff classification pending
Review status
Professional review required before reliance.
- Healthcare Manufacturers
- Structured manufacturer profiles prepared for market-access review.
- Healthcare Markets
- Country intelligence and market-access context across active markets.
- Certification Pathways
- Requirements, timelines, and cost context organized for professional review.
- Trust Model
- Source status, review status, evidence gaps, and next actions remain visible.
160+
Healthcare Manufacturers
34
Healthcare Markets
13
Certification Pathways
Structured
Trust Model
Which market should you prioritize?
Registration, commercial context, network coverage, risk, and readiness — grouped side by side, with a clear recommendation, for every country in a project.
Recommended market
Germany
Best Overall Market
Germany
Defined regulatory pathway, active distributor and hospital interest, and a lower risk profile.
RecommendedFastest Entry
USA
Already approved and commercially active — no new regulatory work required.
91% readyHighest Risk
Saudi Arabia
No distributor identified yet, and the longest estimated regulatory timeline.
High risk| Dimension | |||||
|---|---|---|---|---|---|
| Regulatory | |||||
| Registration | In progress | Source required | Source required | Source required | Reviewed |
| Timeline (est.) | 5–7 mo | 6–9 mo | 5–8 mo | 8–12 mo | 3–5 mo |
| Certificates | CE, ISO 13485 | CE, ISO 13485 | CE/FDA equiv. | SFDA MDMA | 510(k) |
| Import route | EU free circ. | Direct import | PPB clearance | SFDA clearance | FDA cleared |
| Commercial | |||||
| Market size | Large | Medium | Small | Medium | Large |
| Pricing | Regulated | Regulated | Market-set | Tender-based | Market-set |
| Reimbursement | G-BA filing | SGK pathway | Cash-pay | CHI review | CMS coded |
| Network | |||||
| Distributors | 2 identified | 1 identified | 2 identified | 0 identified | Contracted |
| Hospitals | 2 evaluating | 1 evaluating | 3 interested | 0 engaged | 6 active |
| Decision | |||||
| Risk score | Low risk | Medium risk | Medium risk | High risk | Low risk |
| Readiness | 68% | 34% | 41% | 22% | 91% |
GHMAP Recommendation
Germany is currently the strongest non-US launch candidate.
- Defined regulatory pathway
- Active distributor interest
- Hospital evaluation underway
- Lower risk profile
- Stronger launch readiness
Next action
Complete regulatory dossier review.
From market selection to scale — one controlled pathway.
GHMAP connects research, partners, pilots, regulatory work, launch, and post-market growth in one execution journey.
See how every relationship connects to the work.
See who is connected, why the relationship matters, and what action comes next.
Selected network
Germany Market Access Network
Updated automatically as relationships change.
Relationship Inspector
MedBridge Distribution → EZDebride
Next action
Commercial review
Trust
Built for healthcare companies that need real next steps.
Source-tagged deliverables, founder-led review, published pricing, and clear limits — including no patient data on public forms and professional review before business use.
Featured partner
MDM Wound Ventures
Wound care organization
Founder
Dr. James Yentur
Clinician and operator focused on international healthcare commercialization — the recurring market-access gap that led to GHMAP.
Why I built GHMAPWhere GHMAP is operating, right now.
35 Country Intelligence markets in one coordinated view — launch tier, readiness score, and the next recommended step for each market.
Launch tier
- Tier 1 — First wave
- Tier 2 — Second wave
- Tier 3 — Long-term
35 markets from Country Intelligence · click or focus a pin to inspect
Selected Market
Kenya
KE
Next action
Appoint a Kenya-based Local Authorised Agent and evaluate Fasttrack pathway eligibility, particularly if the device already holds US FDA approval given the March 2024 PPB-FDA collaboration agreement.
Live Activity
- Germany Authority Review Updated
- Kenya Pilot Meeting Completed
- Turkey Distributor Qualified
- USA Commercial Launch Approved
What a market connection represents
Reviewed launch planning
Ready for a market-entry outcome?
Book a Market Entry Sprint or a $500 strategy session. You get a reviewed package, clear next actions, and a human review call — not a feature tour.
Professional review remains part of the workflow.